In vivo single cell transcriptomic analysis of microglia and monocyte TAMs under CCL21 inhibition will allow better understanding of the differential impact of CCL21-CCR7 signaling in microglia- or monocyte-derived TAMs during GBM development. This evidence concerns the gene CCL21 and glioblastoma.